Linked Life Data

8679254

Source:http://linkedlifedata.com/resource/pubmed/id/8679254

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1996-8-22
pubmed:abstractText
In this review, we have selected some parameters with the potential to improve the efficacy of RIL and RIT. Focus has partially been on the behaviour of radiolabelled antibodies in vivo in relation to properties and amounts of both target antigen and the antibodies used. If, out of the 28 factors listed in Table 1, some should be given preference in future work, it is our opinion that after the initial saturation of the tumour site a rapid decrease in redundant antibody is of significant importance. Furthermore, quantitative aspects of both antigens and antibodies should be more carefully evaluated when possible. By combining several of the listed approaches toward increasing efficiency, a more extensive use of RIL and RIT could be expected in the future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0284-186X
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-65
pubmed:dateRevised
2009-5-12
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Twenty years with monoclonal antibodies: State of the art--Where do we go?
pubmed:affiliation
Department of Immunology, Umea University, Umea, Sweden.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't